Market Research Logo

Down Syndrome - Epidemiology Forecast-2027

DelveInsight’s ‘Down Syndrome - Epidemiology Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Down Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Down syndrome - Disease Understanding and Treatment Algorithm

The DelveInsight Down Syndrome market report gives the thorough understanding of the Down syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Down syndrome in the US, Europe, and Japan.

Down syndrome Epidemiology

The Down syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic – transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).
According to DelveInsight, the prevalent cases of Down syndrome was 541,538 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Down syndrome with 258,502 prevalent cases in 2016. In 7MM, males had highest prevalent cases of DS as compared to females in 2016. This trend is expected to increase during the study period

Down syndrome Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic – transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).

Report Scope

• The report covers detailed overview of Down syndrome explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Down syndrome
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender, sub-types and diagnosed prevalent population of Down syndrome by clinical manifestation in 7MM

Down syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Down syndrome Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Keys Competition

Down syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Down syndrome market
• Organize sales and marketing efforts by identifying the best opportunities for Down syndrome market
• To understand the future market competition in the Down syndrome market.


1. Key Insights
2. Down syndrome: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Down syndrome in 2016
2.2. Total Market Share (%) Distribution of Down syndrome in 2027
3. Down syndrome: Disease Background and Overview
3.1. Introduction
3.2. Types of Down syndrome
3.3. Etiopathogenesis
3.4. Phenotypic Variability of Down syndrome
3.5. Metabolic Imbalance in Down syndrome
3.6. Clinical Conditions Associated with Down syndrome
3.7. Symptoms of Down syndrome
3.8. Risk factors for Down syndrome
3.9. Genetics Basis of Down syndrome
3.9.1. Gene expression variation
3.10. Diagnosis of Down syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Diagnosed Prevalent Population of Down syndrome in 7MM
5. Country Wise-Epidemiology of Down syndrome
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Diagnosed Prevalent Cases of Down syndrome in the United States
5.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the United States
5.2. EU5 Countries
5.3. Germany
5.3.1. Assumptions and Rationale
5.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Germany
5.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany
6. France
6.1.1. Assumptions and Rationale
6.1.2. Total Diagnosed Prevalent Cases of Down syndrome in France
6.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France
6.2. Italy
6.2.1. Assumptions and Rationale
6.2.2. Total Diagnosed Prevalent Cases of Down syndrome in Italy
6.2.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy
6.3. Spain
6.3.1. Assumptions and Rationale
6.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Spain
6.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain
6.4. United Kingdom
6.4.1. Assumptions and Rationale
6.4.2. Total Diagnosed Prevalent Cases of Down syndrome in the UK
6.4.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK
6.5. Japan
6.5.1. Assumptions and Rationale
6.5.2. Total Diagnosed Prevalent Cases of Down syndrome in Japan
6.5.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan
7. Market Drivers
8. Market Barriers
9. Appendix
9.1. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
List of Tables and Figures
Table 1: Total Prevalent Patient Population of Down Syndrome in 7MM (2016-2027)
Table 2: Total Diagnosed Prevalent Cases of Down Syndrome in the United States (2016-2027)
Table 3: Type-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 4: Sex-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 5: Age-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 6: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the US (2016-2027)
Table 7: Total Diagnosed Prevalent Cases of Down Syndrome in Germany (2016-2027)
Table 8: Type-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 9: Sex-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 10: Age-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 11: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany (2016-2027)
Table 12: Total Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 13: Total Diagnosed Prevalent Cases of Down Syndrome in France (2016-2027)
Table 14: Type-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 15: Sex-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 16: Age-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 17: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France (2016-2027)
Table 18: Total Diagnosed Prevalent Cases of Down Syndrome in Italy (2016-2027)
Table 19: Type-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 20: Sex-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 21: Age-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 22: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy (2016-2027)
Table 23: Total Diagnosed Prevalent Cases of Down Syndrome in Spain (2016-2027)
Table 24: Type-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 25: Sex-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 26: Age-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 27: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain (2016-2027)
Table 28: Total Diagnosed Prevalent Cases of Down Syndrome in the UK (2016-2027)
Table 29: Type-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 30: Sex-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 31: Age-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 32: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK (2016-2027)
Table 33: Total Diagnosed Prevalent Cases of Down Syndrome in Japan (2016-2027)
Table 34: Type-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 35: Sex-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 36: Age-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 37: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan (2016-2027)
Figure 1: Types of Down syndrome
Figure 2: Comparison of balance translocation and translocation DS Karyotype
Figure 3: Comparison of normal and non-disjunction DS Karyotype
Figure 4: Types of Down syndrome
Figure 5: Clinical conditions associated with Down syndrome
Figure 6: Risk Factors for Down syndrome
Figure 7: Candidate dosage sensitive genes on chromosome 21causing DS phenotype
Figure 8: Karyotyping for diagnosis of Down syndrome
Figure 9: Common techniques used for diagnosis of Down’s syndrome along with its advantages and disadvantages
Figure 10: Total Prevalent Patient Population of Down Syndrome in 7MM (2016-2027)
Figure 11: Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 12: Type-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 13: Sex-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 14: Age-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 15: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the US (2016-2027)
Figure 16: Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 17: Type-specific Diagnosed Prevalence of Down Syndrome in the Germany (2016-2027)
Figure 18: Sex-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 19: Age-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 20: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany (2016-2027)
Figure 21: Total Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 22: Type-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 23: Sex-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 24: Age-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 25: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France (2016-2027)
Figure 26: Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 27: Type-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 28: Sex-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 29: Age-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 30: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy (2016-2027)
Figure 31: Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 32: Type-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 33: Sex-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 34: Age-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 35: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain (2016-2027)
Figure 36: Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 37: Type-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 38: Sex-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 39: Age-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 40: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK (2016-2027)
Figure 41: Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 42: Type-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 43: Sex-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 44: Age-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 45: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report